Virtual meeting will give people living with sickle cell disease and caregivers an opportunity to help shape future drug development
HANOVER, Md. – The Sickle Cell Disease Association of America Inc. (SCDAA), together with the Sickle Cell Disease Association of Canada and the Sickle Cell Society in the United Kingdom, will host a virtual meeting designed to bring the voices of people affected by sickle cell disease directly into discussions about future treatments.
The Sickle Cell Voices Alliance will convene the externally led patient-focused drug development (EL-PFDD) meeting, ‘Sickle Cell Disease Voices Shaping Change,‘ on Wednesday, January 27, 2027, from 11 a.m. to 3 p.m. EST (UTC-5).
The meeting will bring together people living with sickle cell disease, caregivers, healthcare professionals, researchers and other stakeholders to share experiences and identify priorities for the development of new therapies.
The organizers say the perspectives gathered will help inform the U.S. Food and Drug Administration (FDA), other regulatory authorities, researchers and drug developers about outcomes that matter to patients and families.
‘This forum brings together sickle cell patient and caregiver voices to ensure early involvement in drug development and encourage the FDA, other regulatory authorities, and key stakeholders to consider a broader range of clinically meaningful endpoints when evaluating therapies for sickle cell disease,’ said Regina Hartfield, president and CEO of SCDAA.
Hartfield added that the meeting is intended to have international relevance and encouraged people affected by sickle cell disease worldwide to participate.
Participants will be able to contribute through live testimony, panel discussions, audience polling and written comments. The information gathered will be summarized in a Voice of the Patient Report, which will be submitted to the FDA and other stakeholders to inform regulatory review, clinical-trial design and future therapeutic development.
International patient voices
The three organizations involved in the Sickle Cell Voices Alliance emphasized the importance of bringing the experiences of the international sickle cell community into drug-development discussions.
John James, CEO of the Sickle Cell Society in the United Kingdom, said the meeting would provide an opportunity for people living with sickle cell disorder, their families and caregivers to communicate directly with those involved in developing future treatments.
‘By listening to the people who understand the realities of sickle cell best, we can build a deeper understanding of its impact and help ensure that new treatments reflect the needs and priorities of the community.’
Biba Tinga, president and executive director of the Sickle Cell Disease Association of Canada, emphasized the importance of measuring treatment outcomes beyond laboratory results.
‘Laboratory results matter, but what matters most is whether a treatment changes a life. We must ensure warrior and caregiver voices guide the development of therapies that deliver improved quality of life, longevity and hope for people living with sickle cell disease.’
How to participate
The meeting will be held virtually on January 27, 2027, from 11 a.m. to 3 p.m. EST.
More information and registration details are available at:
sicklecelldisease.org/ELPFDD2027
